GlaxoSmithKline Invests In Anacor’s Boron-Based Anti-Infectives
This article was originally published in The Pink Sheet Daily
Executive Summary
Discovery and development deal gives Anacor $12 million upfront, with potential to earn more than $2 billion in milestones for eight possible products.
You may also be interested in...
GSK Ends Deal For Anacor’s Antibiotic, Returns Rights
The pharma ended the deal after halting studies on an antibiotic for Gram-negative bacterial infections when some clinical patients showed evidence of microbiological resistance.
Anacor Reworks Collaboration With GSK For Potential Of Additional LeuRS Antibiotics
Six-year deal signed in 2007 may be extended if GSK decides to option additional leucyl-tRNA synthetase candidates discovered by Anacor.
Anacor Reworks Collaboration With GSK For Potential Of Additional LeuRS Antibiotics
Six-year deal signed in 2007 may be extended if GSK decides to option additional leucyl-tRNA synthetase candidates discovered by Anacor.